(CTMX) - Analyzing CytomX Therapeutics's Short Interest
CytomX Therapeutics's (NYSE:CTMX) short percent of float has risen 143.23% since its last report. The company recently reported that it has 8.75 million shares sold short, which is 11.31% of all regul
Shareholders in CytomX Therapeutics (NASDAQ:CTMX) Are in the Red If They Invested Five Years Ago
Biotech Advances in 2024: Innovative Treatments Aim to Boost Pancreatic Cancer Survival Rates
USA News Group – Recognized as one of the most lethal cancers, researchers are striving to improve survival rates for pancreatic cancer patients by...
CytomX Therapeutics Raised to Overweight From Neutral by Piper Sandler
CytomX Therapeutics Raised to Overweight From Neutral by Piper Sandler
Express News | Piper Sandler Upgrades CytomX Therapeutics to Overweight, Raises Price Target to $3.5
Biotech Companies Making Strides in Pancreatic Cancer Treatment and Early Detection
USA News Group – Hope is rising in the fight against one of the deadliest cancers in the world, as a new study recently claimed that a blood test can ...
Shareholders May Find It Hard To Justify Increasing CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) CEO Compensation For Now
Key Insights CytomX Therapeutics will host its Annual General Meeting on 15th of May Total pay for CEO Sean McCarthy includes US$652.1k salary The total compensation is similar to the average for
Analysts' Varied Perspectives On CytomX's CX-904 Cancer Study: Safety Profile But Caution in Pancreatic Cancer
Wednesday, CytomX Therapeutics Inc (NASDAQ:CTMX) released initial data from the ongoing CX-904 Phase 1a dose escalation clinical study, demonstrating a favorable safety profile and confirmed anti-canc
Dow Jumps Over 150 Points; US Foods Posts Upbeat Earnings
U.S. stocks traded higher midway through trading, with the Dow Jones index jumping over 150 points on Thursday.The Dow traded up 0.48% to 39,244.53 while the NASDAQ rose 0.32% to 16,354.20. The S&P 50
Earnings Call Summary | CytomX(CTMX.US) Q1 2024 Earnings Conference
The following is a summary of the CytomX Therapeutics, Inc. (CTMX) Q1 2024 Earnings Call Transcript:Financial Performance:As of Q1 2024, CytomX reported a cash position of $150 million, expected to pr
CytomX Therapeutics Is Maintained at Market Perform by BMO Capital
CytomX Therapeutics Is Maintained at Market Perform by BMO Capital
Express News | HC Wainwright & Co. Reiterates Neutral on CytomX Therapeutics
Tivic Health, RAPT Therapeutics, Notable Labs Among Healthcare Movers
Express News | CytomX Therapeutics Shares Down 39.1% on Questions Over Cancer Therapy's Early-Stage Trial Data
CytomX Therapeutics Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/09/2024 183.69% Wedbush $3 → $8 Upgrades Neutral → Outperform 05/06/2024 183.69% Jefferies $2.5 → $8 Up
Why AppLovin Shares Are Trading Higher By 15%; Here Are 20 Stocks Moving Premarket
Shares of AppLovin Corporation (NASDAQ:APP) rose sharply in today's pre-market trading after the company reported better-than-expected first-quarter financial results.The company posted revenue of $1.
12 Health Care Stocks Moving In Thursday's Pre-Market Session
GainersZai Lab (NASDAQ:ZLAB) stock increased by 21.5% to $20.14 during Thursday's pre-market session. The market value of their outstanding shares is at $1.9 billion. As per the news, the Q1 earnings
Express News | CytomX Therapeutics Inc : Wedbush Raises to Outperform From Neutral; Raises Target Price to $8 From $3
Trending Stocks Today: Pop Culture Shoots up 78.23% Pre-Market
May 9th - US stocks trending pre-market: Gainers: $Pop Culture(CPOP.US)$ surges 78.23% to $3.03 with a turnover of $7.92 million. $Inspire Veterinary Partners(IVP.US)$ soars 33.88% to $4.86 with a tur
Express News | CytomX Therapeutics Shares Are Trading Lower, Pulling Back After Surging After Hours Thursday Following Initial Data From the Ongoing CX-904 Phase 1a Dose Escalation Clinical Study
No Data